These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

930 related items for PubMed ID: 23583193

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A248, a novel synthetic HDAC inhibitor, induces apoptosis through the inhibition of specificity protein 1 and its downstream proteins in human prostate cancer cells.
    Choi ES, Han G, Park SK, Lee K, Kim HJ, Cho SD, Kim HM.
    Mol Med Rep; 2013 Jul; 8(1):195-200. PubMed ID: 23685644
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
    Hsi LC, Xi X, Lotan R, Shureiqi I, Lippman SM.
    Cancer Res; 2004 Dec 01; 64(23):8778-81. PubMed ID: 15574791
    [Abstract] [Full Text] [Related]

  • 27. A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells.
    Yim D, Singh RP, Agarwal C, Lee S, Chi H, Agarwal R.
    Cancer Res; 2005 Feb 01; 65(3):1035-44. PubMed ID: 15705905
    [Abstract] [Full Text] [Related]

  • 28. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells.
    Ahn MY, Jung JH, Na YJ, Kim HS.
    Gynecol Oncol; 2008 Jan 01; 108(1):27-33. PubMed ID: 17920664
    [Abstract] [Full Text] [Related]

  • 29. Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.
    Jeon HS, Ahn MY, Park JH, Kim TH, Chun P, Kim WH, Kim J, Moon HR, Jung JH, Kim HS.
    Int J Oncol; 2010 Aug 01; 37(2):419-28. PubMed ID: 20596669
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
    Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V, Bhalla K.
    Clin Cancer Res; 2005 Sep 01; 11(17):6382-9. PubMed ID: 16144943
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
    Mandl-Weber S, Meinel FG, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P.
    Br J Haematol; 2010 May 01; 149(4):518-28. PubMed ID: 20201941
    [Abstract] [Full Text] [Related]

  • 40. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
    Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS.
    Clin Cancer Res; 2006 Sep 01; 12(17):5199-206. PubMed ID: 16951239
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.